- Home
- DRUG vs MFIN Comparison
DRUG vs MFIN Comparison
Compare DRUG & MFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- MFIN
- Stock Information
- Founded
- DRUG 2019
- MFIN 1995
- Country
- DRUG United States
- MFIN United States
- Employees
- DRUG N/A
- MFIN N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- MFIN Finance: Consumer Services
- Sector
- DRUG Health Care
- MFIN Finance
- Exchange
- DRUG Nasdaq
- MFIN Nasdaq
- Market Cap
- DRUG 233.2M
- MFIN 207.3M
- IPO Year
- DRUG N/A
- MFIN 1996
- Fundamental
- Price
- DRUG $25.95
- MFIN $9.17
- Analyst Decision
- DRUG Strong Buy
- MFIN
- Analyst Count
- DRUG 6
- MFIN 0
- Target Price
- DRUG $83.25
- MFIN N/A
- AVG Volume (30 Days)
- DRUG 29.2K
- MFIN 41.3K
- Earning Date
- DRUG 05-15-2025
- MFIN 07-29-2025
- Dividend Yield
- DRUG N/A
- MFIN 3.60%
- EPS Growth
- DRUG N/A
- MFIN N/A
- EPS
- DRUG N/A
- MFIN 1.60
- Revenue
- DRUG N/A
- MFIN $316,751,000.00
- Revenue This Year
- DRUG N/A
- MFIN N/A
- Revenue Next Year
- DRUG N/A
- MFIN $5.24
- P/E Ratio
- DRUG N/A
- MFIN $5.73
- Revenue Growth
- DRUG N/A
- MFIN 13.91
- 52 Week Low
- DRUG $0.93
- MFIN $6.48
- 52 Week High
- DRUG $79.02
- MFIN $10.50
- Technical
- Relative Strength Index (RSI)
- DRUG 30.05
- MFIN 50.42
- Support Level
- DRUG $26.30
- MFIN $9.14
- Resistance Level
- DRUG $31.20
- MFIN $9.48
- Average True Range (ATR)
- DRUG 2.50
- MFIN 0.31
- MACD
- DRUG -0.55
- MFIN -0.02
- Stochastic Oscillator
- DRUG 5.59
- MFIN 44.83
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.